Children's Mercy Kansas City

SHARE @ Children's Mercy
Care Process Models

Quality Improvement and Clinical Safety

5-2016

Anticoagulation Therapies, Standard Heparin
Children's Mercy Kansas City

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/care_models
Part of the Pediatrics Commons

These guidelines do not establish a standard of care to be followed in every case. It is
recognized that each case is different and those individuals involved in providing health care are
expected to use their judgment in determining what is in the best interests of the patient based
on the circumstances existing at the time. It is impossible to anticipate all possible situations
that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
Recommended Citation
Children's Mercy Kansas City, "Anticoagulation Therapies, Standard Heparin" (2016). Care Process
Models. 11.
https://scholarlyexchange.childrensmercy.org/care_models/11

This Care Process Model is brought to you for free and open access by the Quality Improvement and Clinical Safety
at SHARE @ Children's Mercy. It has been accepted for inclusion in Care Process Models by an authorized
administrator of SHARE @ Children's Mercy. For more information, please contact hlsteel@cmh.edu.

Standard Heparin Management
Care Process Model
Revised May 2016
Fast facts











This guideline is intended for the use of heparin for therapeutic (not prophylactic)
indications. This guideline is not intended for heparin use to maintain patency of arterial or
central venous catheters or hemodialysis/extracorporeal circuits.
Activated partial thromboplastin time (aPTT- reported in Cerner as PTT) and heparin levels
are used to monitor the effects of standard heparin.
Standard heparin is also referred to as unfractionated heparin in many references.
Heparin levels are performed on arrival in the lab (no specific batch time for this test).
Antithrombin III (ATIII) levels are automatically ordered and reported with every heparin
level.
The optimal sample for aPTT and heparin levels is a fresh venipuncture site.
o Alternate sites may be considered but present limitations with interpretation of the
aPTT or heparin levels.
o Capillary samples are not appropriate.
o Samples should never be drawn from an IV containing heparin intended for
therapeutic anticoagulation.
o If aPTT is highly variable, heparin level may provide a more reliable measure.
o Ensure sample is not contaminated by heparin from a heparinized IV line (1/2 or 1
unit/mL heparin) by drawing adequate waste volume to clear line before obtaining
the sample to be tested.
Do not confuse the heparin level with that for fractionated heparin or LMW heparin level.
ATIII is a cofactor for activity of heparin and therefore inadequate serum AT III might be a
cause for poor response to heparin.
This guideline is not intended for patients on ECMO, cardiac bypass pump,
hemodialysis or continuous renal replacement therapy. Refer to specific guideline
for these situations.

Indications



Treatment of venous thromboembolism (VTE).
Treatment of arterial thrombosis.
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Initiation, Maintenance and Duration of Therapy
Initiation of therapy
 Obtain blood for CBC, PT, and aPTT.
 Loading heparin dose: 75-100 units/kg IV over 10 minutes.
o Loading dose may not be indicated in certain clinical situations with
increased bleeding risk
 Calculate initial maintenance heparin dose based on age and weight.
Initial maintenance dose:
≤ 1 year 28 units/kg/hour IV
> 1 year 20 units/kg/hour IV





Obtain blood for aPTT and/or heparin level 4 to 6 hours after administration of the
loading dose (no earlier).
Adjust heparin to maintain the aPTT at 60-85 sec (or an aPTT which usually correlates
to a heparin level of 0.35 to 0.7) using Table 1.
Obtain blood for aPTT and/or heparin level 4 to 6 hours after every change in infusion
rate.
Use heparin level to calibrate aPTT levels. If aPTT is highly variable, heparin level may
provide a more reliable measure. Obtain aPTT at least daily if using heparin levels to
titrate dosing.

Table 1 - Heparin Adjustment
PTT
Bolus
Hold infusion
(seconds)
(units/kg)
(minutes)

Rate change
(units/kg/hour)

Repeat PTT

< 50

50

0

↑10%

4 hours

50-59

0

0

↑ 10%

4 hours

60-85

0

0

no change

24 hours

86-95

0

0

↓10%

4 hours

96-120

0

30

↓10%

4 hours

> 120

0

60

↓15%

4 hours
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Maintenance and monitoring







Once a therapeutic aPTT or heparin level is achieved obtain blood for CBC, PT, aPTT
and/or heparin level at least daily.
Measure platelet counts daily. If platelet count decreases below 150,000/microL or drops
by ≥ 50%, determine if the decrease in platelet count is related to the underlying
disorder or is potentially due to heparin therapy. If likely due to heparin, discontinue
heparin; initiate an alternative therapy and consult hematology. The risk for heparininduced thrombocytopenia (HIT) is greater after 5 days of heparin.
Heparin therapy should be administered in an IV and must not be stopped or interrupted
for any other medications. If the infusion is interrupted for more than 1 hour, reestablish the heparin maintenance infusion at the previous rate and obtain aPTT and
heparin level 4-6 hours later. Once the aPTT level is available, adjust the infusion rate as
indicated by Table 1.
Heparin should be discontinued 6 hours prior to any invasive procedures such as
lumbar puncture or surgery unless the clinical situation requires an emergent
intervention. For conditions necessitating more emergent intervention, utilize protamine
as described in the section Heparin Antidote. Restart 12-24 hours after the procedure or
surgery and when hemostasis has been achieved.

Duration of therapy
The duration of heparin therapy is dependent upon the primary problem.
 General recommendations:
o May start warfarin as early as day 1 if long-term anticoagulation is planned.
o UFH/enoxaparin should be discontinued no earlier than day 6 and after INR
has reached goal range for 2 consecutive days.
o May convert to LMW heparin/enoxaparin when clinical situation allows.

Dietary considerations


None

Potential drug interactions




Increased potential for hemorrhage:
o Concurrent thrombolysis.
o Drugs affecting platelet function such as aspirin, NSAIDs, dipyridamole, clopidogrel,
ticlopidine and cilostazol.
o Complementary/alternative medications known to have potential to increase bleeding
include danshen, devil's claw, dong quai, feverfew, gingko biloba and papain.
Decreased effect of heparin:
o Digoxin, tetracycline, nicotine, antihistamines, and IV nitroglycerin.
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Adverse effects






Bleeding:
o Most common adverse effect.
o Discontinue heparin.
o Refer to Heparin antidote section for management.
Osteoporosis:
o Uncommon.
o Occurs with prolonged heparin therapy.
o Monitor bone density if heparin therapy exceeds 3 months.
Thrombocytopenia due to heparin-induced thrombocytopenia (HIT):
o Risk in children < 2%.
o May be asymptomatic.
o May be associated with life threatening or fatal arterial or venous thrombosis.
o Suspect HIT if platelet count decreases by 50% or decreases below 150,000/microL
between day 5 and 10 of heparin exposure (may occur sooner if patient has
previously been exposed to heparin).
o Consult Hematology if HIT is suspected.

Heparin antidote



Termination of the IV infusion generally will terminate the anticoagulant effect.
If immediate reversal is required, protamine sulfate will result in neutralization of
heparin. The dose of protamine is based on the amount of heparin administered in the
previous 2 hours using Table 2.

Table 2. Protamine sulfate for immediate reversal
Time since last heparin dose Protamine dose/100 units heparin given
<30 minutes

1 mg

30-60 minutes

0.5-0.75 mg

60-120 minutes

0.375-0.5 mg

>120 minutes

0.25-0.375 mg







Maximum Protamine dose is 50 mg.
Protamine should be given IV over 10 minutes. Infusion rate should not exceed 5
mg/min. More rapid infusion may result in hypotension. Patients with hypersensitivity to
fish and those who have received protamine-containing insulin or previous protamine
therapy may be at risk of hypersensitivity reactions.
Obtain an aPTT and PT 15 minutes after the administration of protamine.
Excessive Protamine doses may worsen bleeding potential.
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Other considerations









The optimal sample for aPTT and heparin levels is a fresh venipuncture site.
o Alternate sites may be considered but present limitations with interpretation of the
aPTT or heparin levels.
o Capillary samples are not appropriate.
o Samples should never be drawn from an IV containing heparin intended for
therapeutic anticoagulation.
o If aPTT is highly variable, heparin level may provide a more reliable measure.
o Ensure sample is not contaminated by heparin from a heparinized IV line (1/2 or 1
unit/ml heparin) by drawing adequate waste volume to clear line before obtaining
the sample to be tested.
Avoid aspirin, NSAIDs and other antiplatelet drugs unless required for specific disease
management or clinical situation.
Consider alternative analgesics such as acetaminophen or choline magnesium salicylate
(Trilisate®), as clinically appropriate, if analgesia is required.
Avoid IM injections and arterial punctures.
Heparin should be discontinued 6 hours prior to any invasive procedures such as
lumbar puncture or surgery unless the clinical situation requires an emergent
intervention. For conditions necessitating more emergent intervention, utilize protamine
as described in the section Heparin Antidote. Restart 12-24 hours after the procedure or
surgery and when hemostasis has been achieved.
Mobilization should be encouraged as tolerated.

Indications for Hematology consultation (not all inclusive)








Initiation of therapy for patients
o Age < 30 days
o Baseline INR ≥ 1.2 prior to initiation of warfarin
o Impaired renal function
Maintenance of anticoagulation therapy with
o Delay in reaching therapeutic anticoagulation
o Progression of thrombus
o Concern for heparin induced thrombocytopenia (HIT)
o Hemorrhage and need for antidote
Surgery or invasive procedure in patients with:
o Mechanical/prosthetic mitral valves
o Atrial fibrillation
o Recent/recurrent thromboembolism
Use of LMW heparin other than enoxaparin

Patient Education


Patient education will be initiated when heparin infusion is transitioned to warfarin or
LMW heparin.
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